Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy
Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for (Source: World Pharma News)
Source: World Pharma News - July 16, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

The immune system: T cells are built for speed
Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The exact way that these receptors are distributed over the surface of the T cells is still not completely understood, but the analyses by TU Wien show that previous ideas are no longer tenable. (Source: World Pharma News)
Source: World Pharma News - July 16, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA warns of imposters sending consumers fake warning letters
The U.S. Food and Drug Administration is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or over the phone. Based on the agency's experience with criminals posing as FDA employees, the FDA is concerned that these fake warning letters are linked to an international extortion scam. The FDA generally does not issue warning letters to individuals who purchase medicines online. (Source: World Pharma News)
Source: World Pharma News - July 13, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Amgen and MBC Biolabs announce winners of the Amgen Golden Ticket
Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company receives one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance its scientific programs. (Source: World Pharma News)
Source: World Pharma News - July 12, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Bioengineers create pathway to personalized medicine
Engineering cellular biology, minus the actual cell, is a growing area of interest in biotechnology and synthetic biology. It's known as cell-free protein synthesis, or CFPS, and it has potential to provide sustainable ways to make chemicals, medicines and biomaterials. Unfortunately, a long-standing gap in cell-free systems is the ability to manufacture glycosylated proteins - proteins with a carbohydrate attachment. (Source: World Pharma News)
Source: World Pharma News - July 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer to organize for future growth
Pfizer Inc. (NYSE:PFE) today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. (Source: World Pharma News)
Source: World Pharma News - July 11, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

SMi presents the 13th annual industry leading conference: Cold Chain Distribution
10 - 11 December 2018, London, UK. The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry. (Source: World Pharma News)
Source: World Pharma News - July 11, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Short-term improved vascular function after consuming red raspberries
A recent randomized controlled trial, published in the Archives of Biochemistry and Biophysics, provides insights on the promising outcomes of short-term improvements in blood vessel function among healthy males who consumed dietary achievable amounts of red raspberries. The subjects - ten healthy males aged 18 to 35 - consumed drinks prepared with 200g and 400g of frozen raspberries containing 201 or 403 mg of total polyphenols, or a matched control drink in terms of macro and micronutrient content, color, and taste. (Source: World Pharma News)
Source: World Pharma News - July 10, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

XANTUS programme confirms low bleeding and low stroke rate with Xarelto ® in 11,121 prospectively investigated patients with atrial fibrillation
Results from an analysis of Bayer's XANTUS programme were recently published in the Journal of the American College of Cardiology (JACC)(1). The data confirm the safety profile of the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in routine clinical practice. The analysis highlighted low bleeding and low stroke rates in patients with atrial fibrillation (AF) treated with Xarelto, as well as low rates of treatment discontinuation. (Source: World Pharma News)
Source: World Pharma News - July 10, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Orphan Drugs and Rare Diseases Conference 2018
17 - 18 October, London, UK. Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. At this year's Orphan Drugs and Rare Diseases conference, organised by SMi Group and taking place in London, industry experts will address the opportunities and challenges within the rare disease treatment field. (Source: World Pharma News)
Source: World Pharma News - July 9, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Human clinical trial reveals verapamil as an effective type 1 diabetes therapy
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient's own beta cell function and insulin production - the first such discovery to target diabetes in this manner. (Source: World Pharma News)
Source: World Pharma News - July 9, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA takes steps to encourage more informative labeling on prescription drug and biological products' indications and usage
Today, the U.S. Food and Drug Administration issued a draft guidance to provide recommendations for consideration when drafting the Indications and Usage section of human drug and biological product labeling. The FDA regulations require the Indications and Usage section of drug labeling to state that the drug is indicated for the treatment, prevention, mitigation, cure or diagnosis of a disease or condition, or for the relief of the disease or condition’s symptoms. (Source: World Pharma News)
Source: World Pharma News - July 6, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Researchers develop a new method for turning skin cells into pluripotent stem cells
Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Prize in 2012, that cells from adult skin can be converted to cells typical of early embryos, so-called induced pluripotent stem cells (iPSC). This process is called reprogramming. (Source: World Pharma News)
Source: World Pharma News - July 5, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Data-sharing website may speed the response to new illegal drugs
The drug overdose epidemic currently gripping the nation is so tenacious in part because it's being driven by fentanyl, a synthetic opioid that comes in many forms. Each form has a slightly different chemical structure, and clandestine chemists are constantly cooking up new ones. From a law-enforcement perspective, this makes fentanyl a moving target and very difficult to control. (Source: World Pharma News)
Source: World Pharma News - July 5, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New small molecules pave the way for treating autoinflammatory disease
The innate immune system is the first line of defense, with cells that quickly identify "foreign" motifs from viruses and bacteria and mount up a counterattack to eliminate them. As a key strategy to sense the presence of pathogens, the cells of the innate immune system use receptors that can identify microbial DNA and in turn activate a protein called STING (STimulator of Interferon Genes). Once activated, STING turns on genes that help cells fight off the infecting pathogen. (Source: World Pharma News)
Source: World Pharma News - July 4, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer expands strategic alliance with Broad Institute of MIT and Harvard
Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases such as heart failure. Heart failure - a general diagnosis given when the heart doesn’t pump effectively - is a composite of multiple factors, and as such requires new tools and methods to gain deeper knowledge to benefit patients. (Source: World Pharma News)
Source: World Pharma News - July 4, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

How targeting metabolism can defeat cancer stem cells
Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthrough finding in 2003, Max S. Wicha, M.D., and colleagues discovered that a small number of cells within a tumor - the cancer stem cells - were responsible for fueling the growth and spread of cancer. Kill the stem cells, and you could master the cancer. (Source: World Pharma News)
Source: World Pharma News - July 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck launches online platform fertility.com
Merck, a leading science and technology company, today announces the launch of the new online portal fertility.com. Fertility.com is the entrance to access two unique and bespoke portals: Fertility.com/hcp; developed for fertility Healthcare Professionals (HCPs) Fertility.com/support; created for women, men and couples who are looking for information about fertility and/or are undergoing fertility treatment (Source: World Pharma News)
Source: World Pharma News - July 3, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Can aspirin treat Alzheimer's?
A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological researchers at Rush University Medical Center, who published the results of their study today in the July issue of The Journal of Neuroscience. (Source: World Pharma News)
Source: World Pharma News - July 2, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 18 June 2018 among Foundation Medicine, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 062018 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc. (Source: World Pharma News)
Source: World Pharma News - July 2, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Some existing anti-cancer drugs may act in part by targeting RNA
Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells. The research offers another approach for tackling diseases that have been considered "undruggable," including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers. (Source: World Pharma News)
Source: World Pharma News - June 29, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
Novartis and the European Migraine and Headache Alliance (EMHA) announced initial findings from the largest global migraine patient study to date, involving over 11,000 people from 31 countries. Migraine is a neurological disease which can vary in severity with symptoms ranging from head pain, nausea, vomiting to sensitivity to light. (Source: World Pharma News)
Source: World Pharma News - June 28, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine
Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively, will be presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS) in San Francisco. Results from a one-year study in chronic migraine patients reinforced the established safety and efficacy profile of Aimovig in long-term use. (Source: World Pharma News)
Source: World Pharma News - June 28, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Poliovirus therapy for recurrent glioblastoma has three year survival rate of 21 percent
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment. (Source: World Pharma News)
Source: World Pharma News - June 27, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Immuno-Oncology Conference 2018
26 - 27 September, London, UK. Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress. (Source: World Pharma News)
Source: World Pharma News - June 27, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publication highlights that despite clear or almost clear skin being more achievable than ever before, patients may face a long journey to attain this reality[1]. (Source: World Pharma News)
Source: World Pharma News - June 26, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Delivering insulin in a pill
Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions of people living with type 1 diabetes, a painful needle prick once or twice daily is the only option for delivering the insulin that their bodies cannot produce on their own. (Source: World Pharma News)
Source: World Pharma News - June 26, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. (Source: World Pharma News)
Source: World Pharma News - June 25, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ: FMI) have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. This corresponds to a total transaction value of US$ 2.4 billion on a fully diluted basis, and a total company value of US$ 5.3 billion on a fully diluted basis. (Source: World Pharma News)
Source: World Pharma News - June 25, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Alzheimer's breakthrough: Brain metals that may drive disease progression revealed
Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegenerative condition, by an international research collaboration including the University of Warwick. Dr Joanna Collingwood, from Warwick's School of Engineering, was part of a research team which characterised iron species associated with the formation of amyloid protein plaques in the human brain - abnormal clusters of proteins in the brain. (Source: World Pharma News)
Source: World Pharma News - June 22, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA takes steps to foster greater efficiency in biosimilar development by reconsidering draft guidance on evaluating analytical studies
Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as written, was intended to provide advice for sponsors developing biosimilar products regarding the evaluation of analytical similarity between a proposed biosimilar product and a reference product. After considering public comments that the agency received about the draft guidance, the FDA determined it would withdraw the draft guidance as it gives further consideration to the scientific and regulatory issues involved. (Source: World Pharma News)
Source: World Pharma News - June 21, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Probiotics can protect the skeletons of older women
For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteria, can be used to affect the human skeleton. Among older women who received probiotics, bone loss was halved compared to women who received only a placebo. The research opens the door to a new way to prevent fractures among the elderly. (Source: World Pharma News)
Source: World Pharma News - June 21, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

In mice, stem cells seem to work in fighting obesity! What about stem cells in humans?
Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for weight management in clinical settings, but most are effective only in the short term, since it is common for patients with obesity to gradually regain the weight lost. This unfavourable outcome continues to stimulate researchers to search for an effective long-lasting treatment for obesity. (Source: World Pharma News)
Source: World Pharma News - June 20, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Breast cancer is one of the most common cancers in China - and it is on the rise
Among women in China, rates of breast cancer rose around 3.5% each year between 2000 and 2013. In comparison, breast cancer among American women decreased by about 0.4% a year over the same timeframe. China's rapid urbanisation and development of multiple 'megacities' - a city with 10 million or more inhabitants - reveals higher rates of breast cancer in urban areas, and in more densely-populated areas. (Source: World Pharma News)
Source: World Pharma News - June 20, 2018 Category: Pharmaceuticals Tags: Featured Business and Industry Source Type: news

'Kiss of death' cancer
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients are currently treated by chemotherapy but there is no guarantee of success - and unfortunately, for those that chemotherapy does not work, the survival rate remains only 12 months. (Source: World Pharma News)
Source: World Pharma News - June 19, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes
Kallyope, Inc and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of the agreement, Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialise up to six products discovered in the collaboration. (Source: World Pharma News)
Source: World Pharma News - June 19, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Research shows how a moderate dose of alcohol protects the heart
For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A study conducted at the University of São Paulo's Biomedical Science Institute (ICB-USP) in Brazil suggests that this cardioprotective mechanism may be associated with activation of ALDH2 (aldehyde dehydrogenase-2), (Source: World Pharma News)
Source: World Pharma News - June 18, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Alcon AcrySof ® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens (IOL) compared to the ZEISS AT LISA®* tri 839MP IOL. These findings further strengthen the value of the PanOptix IOL ENLIGHTENTM optical technology, to provide enhanced image quality and more comfortable near to intermediate vision setting the AcrySof IQ PanOptix IOL apart from other trifocal IOLs. (Source: World Pharma News)
Source: World Pharma News - June 18, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Online information on vaccines and autism not always reliable, study shows
Research at Brighton and Sussex Medical School (BSMS) has found that information available online can provide unreliable information based on old, 'weak' scientific studies. The study 'Fake news or weak science?' is published in open-access journal Frontiers in Immunology. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Researchers find link between allergen in red meat and heart disease
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the arteries of the heart. While high saturated fat levels in red meat have long been known to contribute to heart disease for people in general, the new finding suggests that a subgroup of the population may be at heightened risk for a different reason - a food allergen. (Source: World Pharma News)
Source: World Pharma News - June 14, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer announces extension of Zithromax ® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
Pfizer Inc. will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company's 20-years of work to help eliminate the world's leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD). (Source: World Pharma News)
Source: World Pharma News - June 14, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Big data identifies lipids as signatures of health and disease
Biology is swaddled in lipids: fats, oils, and even waxes envelop cells and their organelles, mediate the flow of vast biological information networks, protect fragile tissues, and store essential energy across multiple organisms. But despite their importance, lipids have traditionally been among the hardest biomolecules to study because of the diversity of their molecular structures, which are not determined by the well-defined building blocks and simple rules that govern DNA, RNA, and proteins. (Source: World Pharma News)
Source: World Pharma News - June 13, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

University of Tokyo's RCAST, Fujitsu, and Kowa successfully create promising new compounds to fight drug-resistant cancer
The University of Tokyo's Research Center for Advanced Science and Technology (RCAST), Fujitsu Limited, and Kowa Company Ltd. today announced that using IT-based drug discovery technologies, which entails computer-based virtual design and evaluation, they have successfully created new small molecule compounds that can inhibit cancer-causing "target proteins," and that demonstrate promise against cancers that have shown resistance to existing drugs. (Source: World Pharma News)
Source: World Pharma News - June 13, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

David vs Goliath: How a small molecule can defeat asthma attacks
An invisible particle enters your lungs. The next thing you know breathing becomes difficult. You are having as asthma attack. Asthma is one of the most common and difficult to endure chronic conditions. About 30 million Americans experience asthma attacks and 3 million have a severe, therapy-resistant form of the disease. In some cases, the condition can be fatal. (Source: World Pharma News)
Source: World Pharma News - June 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Update on Phase III clinical trials of lanabecestat for Alzheimer's disease
AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring committee (IDMC), which concluded that both the AMARANTH trial, in early Alzheimer's disease, and the DAYBREAK-ALZ trial, in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility. (Source: World Pharma News)
Source: World Pharma News - June 12, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

How to slow down Ebola
Between 2013 and 2016, West Africa suffered the most severe outbreak of Ebola ever recorded. In Guinea, Sierra Leone and Liberia, a total of 29,000 patients were diagnosed with the disease. More than 11,000 people didn't survive. The epidemic has now passed, but researchers are wondering which intervention strategies would have been most effective in containing the disease. (Source: World Pharma News)
Source: World Pharma News - June 11, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen, Oklahoma Health Care Authority and University of Oklahoma's Pharmacy Management Consultants partner to improve medicaid outcomes
The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) announced a new collaborative agreement to help improve clinical outcomes, experience and satisfaction for Oklahoma's 796,000 SoonerCare (Oklahoma Medicaid) members. Results from the projects also could lay the groundwork for innovative ways to look at patient outcomes and measures for medication reimbursement. (Source: World Pharma News)
Source: World Pharma News - June 11, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

International agreement that human-relevant research is needed to enhance drug discovery
The average pre-approval cost of research and development for a successful drug is estimated to be US$2.6 billion and the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950. More than 90% of drug candidates entering clinical trials fail to gain regulatory approval, mainly as a result of insufficient efficacy and/or unacceptable toxicity, because of the limited predictive value of preclinical, animal-based studies. (Source: World Pharma News)
Source: World Pharma News - June 8, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA grants Priority Review to Roche ’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors. The sBLA is based on data from the phase III HAVEN 3 study. (Source: World Pharma News)
Source: World Pharma News - June 7, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news